Dallas, TX -- (SBWIRE) -- 03/07/2013 -- Marketbuzzreport.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-
Coeur d'Alene Mines Corporation (NYSE:CDE) shares increased 5.62% and closed at $19.17. The company, on Feb. 21, reported fourth quarter net income of $37.6 million or $0.42 per share compared with a net income of $11.4 million, or $0.13 per share in the year ago quarter. Fourth quarter adjusted earnings were $26.2 million or $0.29 per share compared with $43.2 million or $0.48 per share in the fourth quarter 2011. Sales of Metal declined to $205.9 million from $246.9 million last year. Analysts expected the company to report earnings of $0.20 per share on revenues of $230.32 million for the quarter.
Is CDE a Strong Buy After The Recent Gain? Let’s Find out Here
Accuray Incorporated (NASDAQ:ARAY) shares gained 5.59% and closed at $4.53. The company announced that its management was scheduled to present at the Cowen and Company Annual Healthcare Conference in Boston on Tuesday, March 5, 2013 at 9:20 a.m. EST/6:20 a.m. PST.
Additionally, the company, on Feb. 8, announced the pricing of its offering of $100 million aggregate principal amount of 3.50% convertible senior notes due 2018 (the "notes").
Is ARAY a Strong Buying Opportunity After The Recent Slump? Find out Here
Tata Motors Limited (ADR) (NYSE:TTM) shares gained 1.66% to $28.24. The company last month said quarterly profit fell by more than half as earnings dropped at its Jaguar Land Rover business and a weak economy sapped vehicle sales at home. The company reported that its October-December net profit fell to 16.2 billion rupees ($302 million) from 34 billion rupees a year earlier. Jaguar Land Rover, which contributes the bulk of Tata's earnings, suffered a 25 percent fall in quarterly profit to 296 million pounds ($459 million) partly due to marketing and launch costs for a new line or Range Rover vehicles.
Should Investors Consider TTM After The Recent price Action? Get Free Trend Analysis Here
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) shares climbed 5.49% and closed at $5. The company yesterday announced the start of a multicenter, single arm Phase 2 investigator-sponsored study of palifosfamide (ZIO-201) in patients with recurrent metastatic germ cell (testicular and ovarian) tumors who have relapsed on initial platinum-based therapy and high dose chemotherapy, or patients who are not eligible for high dose chemotherapy.
Should Investors Consider ZIOP After The Recent price Action? Get Free Trend Analysis Here
Marketbuzzreport.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. Marketbuzzreport.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed "informational edge" which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at http://www.marketbuzzreport.com
The assembled information disseminated by Marketbuzzreport.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Marketbuzzreport.com does expect that investors will buy and sell securities based on information assembled and presented in Marketbuzzreport.com. PLEASE always do your own due diligence, and consult your financial advisor.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)